Neurocern Demonstrates $370M in Savings for Medicare and Health Insurance Using Artificial Intelligence and Data Analytics Targeted at Alzheimer’s Disease Drug Eligibility

(CHICAGO, IL) — Neurocern announced today a savings outcome of $370M over five years by leveraging artificial intelligence (AI) and neuroinformatics to guide patients to the right Alzheimer’s treatment at the right time. As new disease modifying treatments for Alzheimer’s disease continue to emerge, Medicare and private health insurance plans need data-driven methods to screen, identify, and guide patients to…

My Top Three Takeaways from the 2021 Medicare Supplement Conference in Chicago, Illinois

This month, I had the opportunity to speak at the 2021 Medicare Supplement Summit in Chicago, Illinois. The panel discussed how medical data can be leveraged to predict the cost of care. Read on for my top takeaways from this meeting. 1. Not all analytics are created equal: As the meme above demonstrates, different levels of analytics create new and…

Finding Cognitive Risk Using Medicare Supplement Data and Predictive Analytics

In today’s world, data is king. At Neurocern, we process millions of data fields to find clinical insights. For Medicare supplement data, that means improving risk adjustment accuracy and quality of care. Neurological diseases are the leading cause of disability globally, the second leading cause of death, and a top three condition in health mortality assumptions.  As a result, there…

Dementia Neurology Deserts and Long-Term Care Insurance Claims Experience in the United States

The Neurocern team recently partnered with Milliman and the Society of Actuaries to use our proprietary Alzheimer’s Disease and Related Disorders Neurology Desert Index (ANDI) scores to explore the relationship between geographic distribution of neurology specialists and the incidence of long-term care insurance (LTCI) cognitive claims.